Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review to assess treatments for type 2 diabetes mellitus
11 April 2019 - Report will be subject of New England CEPAC meeting in November 2019; open Input now being accepted until 29 April 2019.
The Institute for Clinical and Economic Review announced today that it plans to assess the comparative clinical effectiveness and value of oral semaglutide (Novo Nordisk) and other treatments for Type 2 diabetes mellitus. The report will likely compare oral semaglutide, a GLP-1 agonist, to three products currently on the market: liraglutide (Victoza, Novo Nordisk), another GLP-1 agonist; empagliflozin (Jardiance, Boehringer Ingelheim and Eli Lilly), a SGLT-2 inhibitor; and sitagliptin (Januvia, Merck), a DPP-4 inhibitor. As part of this review, ICER also may compare oral semaglutide to the sulfonylurea class of drugs as a whole.
Oral semaglutide is currently under FDA review with an anticipated decision in the second half of 2019. An injectable form of semaglutide is already approved by the FDA, marketed by Novo Nordisk under the brand name Ozempic.
